 |
RCCC Limb Salvage and Regeneration Bone Projects
| Clinical Challenges |
Project |
Proposed Therapies |
| Segmental bone loss |
Advanced degradable scaffolds for repair of bone defects |
Biodegradable polymeric scaffolds and composites of polymers with inorganic fillers |
| Bone defects |
Optimizing cell sources for repair of bone defects |
Selective retention of cell populations to enhance scaffolds described above; MSD with bioactive agents (i.e., protein, peptide) |
Bone injury
|
Molecular Surface Design (MSD) for controlled cell- and tissue-scaffold interactions |
Protein-based growth factor - MSD; Peptide-based - MSD |
Advanced Degradable Scaffolds for Repair of Bone Defects
Sometimes, the body’s natural processes are not enough to repair a fracture site. This project seeks to repair fractured bone by implanting a scaffold to support growth of both adjacent bone cells and transferred bone marrow cells and more effectively bridge bone defects.
The scaffolds are fabricated from new synthetic biomaterials that are specifically selected and designed to stimulate and guide the attachment and migration of bone forming cells and new blood vessels into the repair site. As the bone regenerates, the scaffolds are designed to degrade harmlessly, leaving only natural tissue behind. Enhancements to the scaffolds include new polymer materials, new three dimensional structures that mimic natural bone.
|
Scaffolds to Aid the Formation
of New Bone in Injury Sites
|
|
Mayo Clinic, Tissue Engineering and Biomaterials Laboratory, Michael Yaszemski, MD, PhD
Rutgers, New Jersey Center for Biomaterials, Joachim Kohn, PhD
Arteriocyte, Inc., Cleveland, OH
BonWrx, Inc., Phoenix, AZ
Trident Biomedical, Inc., Somerville, NJ
|
Optimizing Cell Sources for Repair of Bone Defects
Cells that are capable of forming new bone tissue, called osteogenic connective tissue progenitors (CTP-Os), are essential to successful bone formation. The researchers are comparing current techniques for harvesting and manipulating CTP-Os from bone marrow, developing new methods, and determining which practices provide the most effective source of CTP-Os for combination with existing scaffolds and for new scaffolds being developed in related AFIRM projects.
|
Machine used for rapid concentration and selection of stem cells in the operating room
|
|
Cleveland Clinic, Orthopaedic and Rheumatologic Research Center and the Clinical Tissue Engineering Center, George Muschler, MD
Integra Spine, Akron, OH
|
Molecular Surface Design (MSD) for Controlled Cell- and Tissue-Scaffold Interactions
The goal of this project is to develop a molecular surface design method to improve control over the response of cells and tissues to implanted materials. Specifically, these researchers attach bioactive materials to the surface of bone scaffolds. The surface coatings involve attaching molecules that stimulate the attachment, growth and survival of bone forming cells (CTP-Os) and offer a potent method for further improvement upon the advanced scaffolds being developed in other AFIRM projects.
|
Protein molecules tethered to
the surface of a scaffold
|
|
Cleveland Clinic, Orthopaedic and Rheumatologic Research Center and the Clinical Tissue Engineering Center, George Muschler, MD
MIT, Biotech/Pharma Engineering Center, Linda Griffith, PhD
Stony Brook University, Center of Tissue Engineering, Director, Richard Clark, MD
Rutgers, New Jersey Center for Biomaterials, Joachim Kohn, PhD
Integra Spine, Akron, OH
|
|
|
|
